Trovagene (NASDAQ:TROV) began enrollment for its Phase 1b/2 study of onvansertib for the treatment of patients with metastatic colorectal cancer (mCRC).
The trial will assess the safety and efficacy of onvansertib, in combination with standard-of-care FOLFIRI and Avastin, for second‑line treatment of mCRC in patients with a KRAS mutation.
The company noted that some 50% of mCRC patients have this mutation, but their current treatment response rate is just 5%.
“We are targeting these patients in this trial because in onvansertib preclinical studies, tumor cells that harbor KRAS mutations, when treated with onvansertib, have what we call ‘synthetic lethality,’ or in other words, have a greater susceptibility to tumor cell death,” Dr. Heinz-Josef Lenz, one of the study’s investigators, said in a statement.
Expected to enroll up to 44 patients, the trial will be conducted at USC Norris Comprehensive Cancer Center, Hoag Cancer Center and the Mayo Clinic.
